Feb 25 (Reuters) - Contract drug manufacturer Thermo Fisher Scientific TMO.N said on Tuesday it will buy Solventum's SOLV.N purification and filtration business for about $4.1 billion in cash.
The transaction is expected to be completed by the end of 2025.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
((Christy.Santhosh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。